Medical Information Services Sample Clauses

Medical Information Services. 5.5.1 DISTRIBUTOR shall provide medical information services for the Product in the Territory through qualified personnel in accordance with this Agreement and as further detailed in this Section 5.5. Medical queries from the Territory received by the SUPPLIER shall be directed to DISTRIBUTOR´s Address for Medical Information Purposes as further detailed in ANNEX J.
AutoNDA by SimpleDocs
Medical Information Services. On or before the Effective Date, MPL shall provide to Distributor, MPL's current database of Medical Information Letters regarding the Licensed Products; provided, however, that Distributor shall be solely responsible and liable for any use or modification of such Medical Information Letters by Distributor. MPL shall refer all requests and inquiries from healthcare professionals and consumers of the Licensed Products to Distributor, and Distributor will provide to MPL the telephone number to which such call will be referred. Distributor and MPL have jointly developed written procedures for the administration of and response to medical inquiries concerning the Licensed Products by consumers, physicians, pharmacists and other health care professionals, as set forth in EXHIBIT 6.05. Distributor and MPL shall each comply with the provisions thereof.
Medical Information Services. Wyeth shall remain responsible for responding to any and all medical inquiries received before the Closing Date. Wyeth shall satisfy these requirements within thirty (30) days after the Closing Date. From and after the Closing Date, Genzyme shall be solely responsible for all medical information support related to all medical inquiries received from and after the Closing Date, including but not limited to: provision of standard medical responses, custom creation of medical responses, maintaining a medical inquiry database which captures the nature of the inquiry and the response provided, literature review for relevant Synvisc-related publications and appropriate capture and forwarding of post-marketing adverse events and product complaints. In the event that Wyeth receives any medical inquiry or request related to Synvisc Product after the Closing Date, Wyeth shall promptly refer such inquiry to an individual designated by Genzyme. [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Medical Information Services. On or within [***] after the Effective Date, Santarus will provide to GSK, Santarus’ current database of Medical Information Letters (if any) regarding the PR Product; provided, however, that GSK will be solely responsible and liable for any use or modification of such Medical Information Letters by GSK. From and after the Effective Date, at GSK’s cost and expense, Santarus will promptly refer all requests and inquiries from healthcare professionals and consumers of the PR Product in the Territory to GSK, and GSK will provide to Santarus the telephone number to which such call will be referred. Within thirty (30) days of the Effective Date and prior to launch, GSK and Santarus will jointly develop written procedures for the administration of, and response to, medical inquiries concerning PR Product in the Territory by consumers, physicians, pharmacists and other health care professionals. GSK and Santarus will each comply with the provisions thereof at GSK’s cost and expense.
Medical Information Services. DURA and BMS have jointly developed written procedures for the administration of and response to medical inquiries concerning the Products by consumers, physicians, pharmacists and other health care professionals, as set forth in EXHIBIT 6.2. DURA and BMS shall each comply with the provisions thereof.
Medical Information Services. On or before the Commencement Date, GSK will provide to Myogen, GSK's current database of Medical Information Letters regarding the Product; provided, however, that Myogen will be solely responsible and liable for any use or modification of such Medical Information Letters by Myogen. From and after the Commencement Date, GSK will refer all requests and inquiries from healthcare professionals and consumers of the Product to Myogen, and Myogen will provide to GSK the telephone number to which such call will be referred. Within thirty (30) days of the Effective Date, Myogen and GSK will jointly developed written procedures for the administration of and response to medical inquiries concerning Product by consumers, physicians, pharmacists and other health care professionals. Myogen and GSK will each comply with the provisions thereof.

Related to Medical Information Services

  • Information Services The Custodian may rely upon information received from issuers of Securities or agents of such issuers, information received from Subcustodians or depositories, information from data reporting services that provide detail on corporate actions and other securities information, and other commercially reasonable industry sources; and, provided the Custodian has acted in accordance with the standard of care set forth in Section 6 (a), the Custodian shall have no liability as a result of relying upon such information sources, including but not limited to errors in any such information.

  • Technical Information Methods, processes, formulae, compositions, systems, techniques, inventions, machines, computer programs and research projects, unpatented inventions, designs, know-how, trade secrets, technical information and data, specifications, blueprints, transparencies, test data, and additions, modifications, and improvements thereon which are revealed to Employee.

  • Shareholder Information Services (i) Make information available to shareholder servicing unit and other remote access units regarding trade date, share price, current holdings, yields, and dividend information.

  • Marketing Services The Manager shall provide advice and assistance in the marketing of the Vessels, including the identification of potential customers, identification of Vessels available for charter opportunities and preparation of bids.

  • Product Information Galapagos recognizes that by reason of, inter alia, Xxxxxx’x status as an exclusive licensee pursuant to the grants under Section 5.2, Xxxxxx has an interest in Galapagos’ retention in confidence of certain information of Galapagos. Accordingly, during the Term, Galapagos shall, and shall cause its Affiliates and its and their respective officers, directors, employees, and agents to, keep completely confidential, and not publish or otherwise disclose, and not use directly or indirectly for any purpose other than to fulfill Galapagos’ obligations hereunder any Information owned or otherwise Controlled by Galapagos or any of its Affiliates specifically relating to any Licensed Compound or Licensed Product, or the Exploitation of any of the foregoing (the “Product Information”); except to the extent (x) the Product Information is in the public domain through no fault of Galapagos, its Affiliates or any of its or their respective officers, directors, employees, or agents; (y) such disclosure or use is expressly permitted under Section 9.3, or (z) such disclosure or use is otherwise expressly permitted by the terms of this Agreement. For purposes of Section 9.3, Xxxxxx shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Galapagos shall be deemed to be the receiving Party with respect thereto. For further clarification, (i) without limiting this Section 9.1, to the extent Product Information is disclosed by Galapagos to Xxxxxx pursuant to this Agreement, such information shall, subject to the other terms and conditions of this Article 9, also constitute Confidential Information of Galapagos with respect to the use and disclosure of such Information by Galapagos (and Galapagos shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Xxxxxx shall be deemed to be the receiving Party with respect thereto), but (ii) the disclosure by Galapagos to Xxxxxx of Product Information shall not cause such information to cease to be subject to the provisions of this Section 9.1 with respect to the use and disclosure of such Confidential Information by Galapagos. If this Agreement is terminated in its entirety or with respect to the Terminated Territory, this Section 9.1 shall have no continuing force or effect with respect to the use or disclosure of such information solely in connection with the Exploitation of the Licensed Compound or Licensed Product for the benefit of the Terminated Territory, but the Product Information, to the extent disclosed by Xxxxxx to Galapagos hereunder, shall continue to be Confidential Information of Xxxxxx, subject to the terms of Sections 9.2, 9.3, and 9.7 for purposes of the surviving provisions of this Agreement.

  • Hosting Services GSI shall load the Web site onto server(s) that are connected to the Internet and readily accessible via the Web through use of the Domain Names. GSI shall ensure that the Web site is functional and ready to process transactions in a reasonably efficient manner.

  • Services to Others Clients Nothing contained in this Agreement shall limit or restrict (i) the freedom of the Sub-adviser, or any affiliated person thereof, to render investment management and corporate administrative services to other investment companies, to act as investment manager or investment counselor to other persons, firms, or corporations, or to engage in any other business activities, or (ii) the right of any director, officer, or employee of the Sub-adviser, who may also be a director, officer, or employee of the Fund, to engage in any other business or to devote his or her time and attention in part to the management or other aspects of any other business, whether of a similar nature or a dissimilar nature.

  • Support Services Other than the assistance provided in the Information, the BNPP Entities do not offer any support services in connection with the Software.

  • Third Party Services Any services required for or contemplated by the performance of the above-referenced services by the Administrator to be provided by unaffiliated third parties (including independent auditors’ fees and counsel fees) may, if provided for or otherwise contemplated by the Financing Order and if the Issuer deems it necessary or desirable, be arranged by the Issuer or by the Administrator at the direction (which may be general or specific) of the Issuer. Costs and expenses associated with the contracting for such third-party professional services may be paid directly by the Issuer or paid by the Administrator and reimbursed by the Issuer in accordance with Section 2, or otherwise as the Administrator and the Issuer may mutually arrange.

  • Sales Material, Information and Trademarks 6.1 For purposes of this Section 6, "Sales literature or other Promotional material" includes, but is not limited to, portions of the following that use any logo or other trademark related to the Trust, or Underwriter or its affiliates, or refer to the Trust: advertisements (such as material published or designed for use in a newspaper, magazine or other periodical, radio, television, telephone or tape recording, videotape display, signs or billboards, motion pictures, electronic communication or other public media), sales literature (i.e., any written communication distributed or made generally available to customers or the public, including brochures, circulars, research reports, market letters, form letters, seminar texts, reprints or excerpts or any other advertisement, sales literature or published article or electronic communication), educational or training materials or other communications distributed or made generally available to some or all agents or employees in any media, and disclosure documents, shareholder reports and proxy materials.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!